Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 15/20 | 0.49 |
| ▸ | CRBN | Q96SW2 | 15/20 | 0.49 |
| ▸ | TNF | P01375 | 1/20 | 0.40 |
| ▸ | IL1B | P01584 | 1/20 | 0.40 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.40 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.40 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 4/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15468272 | 0.92 | DDB1 (0.60) | DDB1CRBNTNFIL1BTBXA2R | |
| SCHEMBL15468173 | 0.87 | DDB1 (0.49) | DDB1CRBNTNFIL1BTBXA2R | |
| SCHEMBL15468182 | 0.85 | DDB1 (0.49) | DDB1CRBNTNFIL1BTBXA2R | |
| SCHEMBL15468179 | 0.85 | DDB1 (0.52) | DDB1CRBNTNFIL1BTBXA2R | |
| SCHEMBL15468185 | 0.85 | DDB1 (0.49) | DDB1CRBNTNFIL1BTBXA2R | |
| SCHEMBL15468183 | 0.84 | CRBN (0.48) | DDB1CRBNTNFIL1BTBXA2R | |
| SCHEMBL15468180 | 0.84 | DDB1 (0.48) | DDB1CRBNTNFIL1BTBXA2R | |
| SCHEMBL14072308 | 0.83 | CRBN (0.47) | DDB1CRBNTNFIL1BTBXA2R | |
| SCHEMBL15468178 | 0.83 | DDB1 (0.53) | DDB1CRBNTNFIL1BTBXA2R | |
| SCHEMBL15468181 | 0.82 | CRBN (0.49) | DDB1CRBNIKZF3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140314752-A1 | METHODS FOR TREATING CANCER USING TOR KINASE INHIBITOR COMBINATION THERAPY | SIGNAL PHARMACEUTICALS, LLC (US) | 2014-10-23 | — | — | US | disclosed |
| US-8648096-B2 | N-methylaminomethyl isoindole compounds and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2014-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140314752-A1 | METHODS FOR TREATING CANCER USING TOR KINASE INHIBITOR COMBINATION THERAPY | MTOR, ULK1, RICTOR | DDB1 820/4885CRBN 869/4885TNF 798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.